Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRN-001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SRN-001 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SRN-001 | DRUG | siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized |
| Placebo | DRUG | 0.9% Sodium Chloride(Normal saline) |
Inclusion Criteria: * Age 18-70 * BMI ≥18.0 kg/㎡ and ≤35 kg/㎡ * 12-lead triplicate electrocardiogram (ECG) readings within normal limits or with no clinically significant abnormalities * systolic blood pressure ≥ 90 mmHg and ≤160 mmHg; a diastolic blood pressure ≥ 50 mmHg and ≤95 mmHg; pulse ≥ 45 b...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
SRN-001 is an investigational small molecule being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease. It is currently in clinical development and has not been approved by regulatory authorities.
SRN-001 is being developed by cbdMD, Inc., a company publicly traded under the ticker symbol YCBD on the NYSE American exchange. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
SRN-001 is in Phase 1 clinical development. A first-in-human study has been completed, and the drug remains investigational. It has not received regulatory approval and is still undergoing clinical evaluation for safety and tolerability.
SRN-001 has one completed Phase 1 clinical trial, identified as NCT05984992, titled 'The First-in-human Study of SRN-001 in Healthy Participants.' This randomized, double-blind, placebo-controlled study enrolled 25 participants in Australia and included healthy volunteers aged 18 years and older.
No alternative names for SRN-001 have been disclosed. It is identified solely by its developmental code name SRN-001 in clinical trial registries and company communications.